Driven by Science. Defined by Purpose.
Oncorus was founded on the conviction that self-amplifying RNA represents a fundamentally new class of cancer medicine — one with the potential to transform outcomes for patients with the most difficult-to-treat malignancies.
Our Mission
To realize the full promise of self-amplifying RNA medicines and deliver transformative therapies to cancer patients who need them most.
Scientific Rigor
Every program is grounded in deep mechanistic understanding. We advance only what the science supports.
Patient Focus
Our decisions are guided by the patients we aim to serve — those with limited options and urgent need.
Collaborative Spirit
We partner with leading academic institutions, clinical investigators, and industry collaborators to accelerate progress.
Integrity
We hold ourselves to the highest standards of scientific and ethical conduct in everything we do.
Company History
Oncorus was founded to address a fundamental gap in oncology: the lack of a systemic RNA medicine capable of reaching disseminated tumors and activating the immune system at scale.
Oncorus founded; saRNA platform technology licensed from leading academic institutions
Series A financing closed; LNP delivery optimization program initiated
IND filed for ONC-001; Phase 1 dose-escalation study initiated in advanced solid tumors
Phase 1 interim data presented at AACR; ONC-002 preclinical program advanced
ONC-003 discovery program initiated; Series B financing closed to fund pipeline expansion
Join Us
We are building a team of exceptional scientists, clinicians, and operators who share our commitment to transforming cancer treatment. Explore open positions or reach out to learn more.